Cubist Systematic Strategies LLC Purchases New Position in Delcath Systems, Inc. (NASDAQ:DCTH)

Cubist Systematic Strategies LLC acquired a new position in Delcath Systems, Inc. (NASDAQ:DCTH) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 44,222 shares of the company’s stock, valued at approximately $370,000. Cubist Systematic Strategies LLC owned approximately 0.16% of Delcath Systems at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in DCTH. Vanguard Group Inc. boosted its holdings in Delcath Systems by 31.0% during the first quarter. Vanguard Group Inc. now owns 683,686 shares of the company’s stock worth $3,261,000 after buying an additional 161,678 shares in the last quarter. BVF Inc. IL raised its holdings in Delcath Systems by 23.1% in the 1st quarter. BVF Inc. IL now owns 1,202,067 shares of the company’s stock worth $5,734,000 after purchasing an additional 225,918 shares during the period. Levin Capital Strategies L.P. boosted its position in Delcath Systems by 12.2% during the first quarter. Levin Capital Strategies L.P. now owns 54,969 shares of the company’s stock worth $262,000 after purchasing an additional 5,969 shares in the last quarter. Rosalind Advisors Inc. grew its holdings in Delcath Systems by 155.1% in the second quarter. Rosalind Advisors Inc. now owns 2,650,389 shares of the company’s stock valued at $22,184,000 after purchasing an additional 1,611,561 shares during the period. Finally, Legato Capital Management LLC purchased a new stake in shares of Delcath Systems in the second quarter valued at approximately $966,000. Institutional investors and hedge funds own 61.12% of the company’s stock.

Delcath Systems Trading Up 1.7 %

Shares of NASDAQ DCTH opened at $8.32 on Monday. The company has a 50-day moving average of $8.94 and a 200 day moving average of $7.57. Delcath Systems, Inc. has a 12-month low of $2.25 and a 12-month high of $11.74. The stock has a market cap of $231.21 million, a PE ratio of -3.26 and a beta of 0.78.

Delcath Systems (NASDAQ:DCTH) last posted its quarterly earnings results on Monday, August 5th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.12). The company had revenue of $7.77 million during the quarter, compared to analyst estimates of $5.00 million. Delcath Systems had a negative net margin of 474.22% and a negative return on equity of 312.48%. During the same period in the prior year, the business posted ($0.58) EPS. On average, sell-side analysts forecast that Delcath Systems, Inc. will post -1.67 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently commented on DCTH. Craig Hallum initiated coverage on shares of Delcath Systems in a report on Friday, June 28th. They issued a “buy” rating and a $18.00 price target for the company. Stephens reaffirmed an “overweight” rating and issued a $25.00 price target on shares of Delcath Systems in a research note on Tuesday, August 6th. HC Wainwright reiterated a “buy” rating and set a $22.00 price objective on shares of Delcath Systems in a research note on Tuesday, August 6th. Finally, StockNews.com upgraded Delcath Systems from a “sell” rating to a “hold” rating in a research report on Friday, September 27th.

Delcath Systems Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.